Physician profile
Philip Nimoityn
NPI 1497864375
$13,057.50
in general payments reported to CMS, 2019-2025
13 companies · $8,663 in 2025
The $8,663 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.08 · 2022: $12.28 · 2024: $4,286 · 2025: $8,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,425.00 |
| Food and Beverage | $1,524.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agepha Pharma Fz LLC | $6,403.53 | 2024-2025 | Lodoco |
| Infobionic, INC | $5,425.00 | 2024-2025 | Mome Device |
| Bridgebio Pharma, INC. | $442.79 | 2025 | Attruby |
| Novo Nordisk INC | $196.29 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Alnylam Pharmaceuticals INC. | $127.27 | 2025 | Onpattro |
| Cleerly, INC. | $127.07 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Amgen INC. | $103.59 | 2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $96.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $63.96 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $24.44 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.24 | 2025 | Jardiance |
| Abbott Laboratories | $13.96 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Nimoityn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.